Journal Article Review Research Support, Non-U.S. Gov't Epublish 7 citations
PubMed: 38002311 DOI: 10.3390/biom13111629
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
Biomolecules 13(11)
Authors: Niyati Seshagiri Sharma, Bibha Choudhary
Affiliations
- Institute of Bioinformatics and Applied Biotechnology (IBAB), Electronic City, Bengaluru 560100, India. Manipal Academy of Higher Education (MAHE), Manipal 576104, India.
- Institute of Bioinformatics and Applied Biotechnology (IBAB), Electronic City, Bengaluru 560100, India.
Abstract
Multiple myeloma (MM) is a dyscrasia of plasma cells (PCs) characterized by abnormal immunoglobulin (Ig) production. The disease remains incurable due to a multitude of mutations and structural abnormalities in MM cells, coupled with a favorable microenvironment and immune suppression that eventually contribute to the development of drug resistance. The bone marrow microenvironment (BMME) is composed of a cellular component comprising stromal cells, endothelial cells, osteoclasts, osteoblasts, and immune cells, and a non-cellular component made of the extracellular matrix (ECM) and the liquid milieu, which contains cytokines, growth factors, and chemokines. The bone marrow stromal cells (BMSCs) are involved in the adhesion of MM cells, promote the growth, proliferation, invasion, and drug resistance of MM cells, and are also crucial in angiogenesis and the formation of lytic bone lesions. Classical immunophenotyping in combination with advanced immune profiling using single-cell sequencing technologies has enabled immune cell-specific gene expression analysis in MM to further elucidate the roles of specific immune cell fractions from peripheral blood and bone marrow (BM) in myelomagenesis and progression, immune evasion and exhaustion mechanisms, and development of drug resistance and relapse. The review describes the role of BMME components in MM development and ongoing clinical trials using immunotherapeutic approaches.
MeSH
Growth, Drug Resistance, Hematopoiesis, Immunotherapy, Bone Marrow, Genes, Multiple Myeloma, Stromal Cells, Tumor Microenvironment
Cited by
- Using protein turnover assay to explore the drug mechanism of Carfilzomib. Acta Biochim Biophys Sin (Shanghai), 2025
- Topography-based implants for bone regeneration: Design, biological mechanism, and therapeutics. Mater Today Bio, 2025
- The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen. Sci Rep, 2025
- Single-cell sequencing reveals the mechanisms of multiple myeloma progression: clarity or confusion? Ann Hematol, 2025
- Maraviroc enhances Bortezomib sensitivity in multiple myeloma by inhibiting M2 macrophage polarization via PI3K/AKT/RhoA signaling pathway in macrophages. Cell Div, 2025